Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roivant and Poxel join for imeglimin

by Michael McCoy
February 19, 2018 | A version of this story appeared in Volume 96, Issue 8

Roivant Sciences, an investment vehicle of biotech investor Vivek Ramaswamy, will put $50 million into the French biotech firm Poxel in exchange for worldwide rights, except in Asia, to Poxel’s developmental diabetes treatment imeglimin. The drug is in Phase III trials in Japan with Poxel’s Asian partner, Sumitomo Dainippon Pharma. Poxel says its drug works by increasing insulin secretion and cutting glucose production.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.